Stock Price of Aptose Biosciences, Inc. (APTO) Increases 17%

Aptose Biosciences, Inc.s in-depth stock price analysis indicates that the stock price has rallied 30.42% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -46.82% . Looking at the past 52 week period, the stock price is down -55.1% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Aptose Biosciences, Inc. has a negative value of -53.67 compared to overall market performance. Aptose Biosciences, Inc. (NASDAQ:APTO) has climbed 17% in the past week and advanced 2.63% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 16.06% and the outperformance has advanced to 0.79% for the last 4 weeks period.

Aptose Biosciences, Inc. (NASDAQ:APTO) : On Friday heightened volatility was witnessed in Aptose Biosciences, Inc. (NASDAQ:APTO) which led to swings in the share price. The stock opened for trading at $1.13 and hit $1.22 on the upside , eventually ending the session at $1.17, with a gain of 6.36% or 0.07 points. The heightened volatility saw the trading volume jump to 1,268,612 shares. The 52-week high of the share price is $4.2999 and the company has a market cap of $16 million. The 52-week low of the share price is at $0.834 .

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Aptose Biosciences Inc was Reiterated by RBC Capital Mkts on Nov 16, 2016 to Outperform, Lowers Price Target to $ 12 from a previous price target of $18 .

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada.


Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.